Aquestive Therapeutics, Inc. Cash Flow Statement
AQST|8 years of annual SEC 10-K data (FY2018-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
Aquestive Therapeutics, Inc. used $52M in operating cash flow and negative free cash flow of $53M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$83.8M | -$44.1M | -$7.9M | -$54.4M | -$55.8M | -$66.2M | -$61.4M | -$8.9M |
| Depreciation & Amortization | $548.0K | $718.0K | $1.3M | $2.4M | $3.4M | $2.9M | $3.2M | $3.8M |
| Operating Cash Flow | -$52.4M | -$35.8M | -$6.4M | -$9.8M | -$45.5M | -$60.2M | -$13.0M | $5.8M |
| Capital Expenditures | $562.0K | $159.0K | $995.0K | $1.0M | $517.0K | $663.0K | $1.8M | $2.1M |
| Free Cash Flow | -$53.0M | -$35.9M | -$7.4M | -$10.8M | -$46.0M | -$60.9M | -$14.8M | $3.8M |
| FCF Margin | -119.0% | -62.4% | -14.6% | -22.7% | -100.3% | -115.7% | -22.0% | 5.6% |